News Breaks |
|
|
| November 14, 2012 |
| 06:31 EDT |  | EW | Edwards Lifesciences downgraded to Sell from Neutral at UBS
UBS downgraded Edwards Lifesciences due to the slower than expected U.S. Sapien launch and European deceleration. Price target lowered to $80 from $95. |
|
|
News For EW From The Last 14 Days Check below for free stories on EW the last two weeks. |
|
|
| May 21, 2013 |
| 10:46 EDT |  | EW | Edwards Lifesciences announces positive outcomes from study of SAPIEN XT
 Subscribe for More Information |
|
| May 15, 2013 |
| 07:17 EDT |  | EW | Edwards Lifesciences share repurchases positive, says Wells Fargo
Subscribe for More Information |
|
| May 14, 2013 |
| 09:27 EDT | | EW | Edwards Lifesciences CEO to purchase $5M of company stock
The company announced that Michael A. Mussallem, Edwards' chairman and CEO, will make a $5M cash purchase of newly issued shares of Edwards common stock. |
|
| 09:26 EDT | | EW | Edwards Lifesciences announces new $750M share repurchase program
Edwards Lifesciences announced that its board has authorized a new share repurchase program to acquire up to an additional $750M of the company's outstanding common shares. As of March 31, Edwards had approximately $140M remaining of its current $500M share repurchase program, which was authorized in September 2011. Edwards expects to utilize the remainder of the $500M repurchase authorization during Q2. |
|
| 09:22 EDT | | EW | Edwards Lifesciences CFO announces retirement
Edwards Lifesciences announced that Thomas M. Abate, the company's CFO, plans to retire later this year. Abate plans to remain CFO until his successor is in place. The company has retained Peter Crist of Crist/Kolder Associates to assist in the CFO search. |
|
|
|
|
|
